Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their 1,000th WATCHMAN device procedure, a minimally invasive solution for ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...

CAMBRIA COUNTY, Pa (WJAC) — Conemaugh Memorial Medical Center reached a significant milestone this week by successfully performing their 300th procedure with the "watchman" device. The "watchman left ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am a 70-year old woman with a prior history of ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The Watchman left atrial appendage (LAA) closure device (Boston Scientific) is associated with low 1-year stroke rates, despite being used commercially in older, sicker patients than seen in pivotal ...